


PHARMACEUTICAL 2022

Design Therapeutics Inc. Rank 40 of 475





PHARMACEUTICAL 2022



Design Therapeutics Inc. Rank 40 of 475

The relative strengths and weaknesses of Design Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Design Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 172% points. The greatest weakness of Design Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 414% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	385,435
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,283
Liabilities, Non-Current	3,144
Other Assets	3,614
Other Compr. Net Income	-400
Other Expenses	0
Other Liabilities	0
Other Net Income	298
Property and Equipment	1,508
Research and Development	24,778
Revenues	0
Selling, General and Administrative Expense	11,053

Output Variable	Value in 1000 USD
Assets	390,557
Liabilities	8,427
Expenses	35,831
Stockholders Equity	382,130
Net Income	-35,533
Comprehensive Net Income	-35,733
Economic Capital Ratio	138%